Heidelberg Pharma AG (XTER:HPHA) EV-to-EBIT : -5.89 (As of May. 25, 2024)

Heidelberg Pharma AG EV-to-EBIT Chart

Heidelberg Pharma AG Annual Data
	Trend	Nov14	Nov15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22	Nov23
EV-to-EBIT		Get a 7-Day Free Trial					-5.17	-8.54	-7.08	-11.87	-4.65

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															-10.07	-5.13	-5.51	-4.65	-6.21

Competitive Comparison of Heidelberg Pharma AG's EV-to-EBIT

For the Biotechnology subindustry, Heidelberg Pharma AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's EV-to-EBIT falls into.

Heidelberg Pharma AG EV-to-EBIT Calculation

Heidelberg Pharma AG's EV-to-EBIT for today is calculated as:

Heidelberg Pharma AG's current Enterprise Value is €104.54 Mil.
Heidelberg Pharma AG's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG  (XTER:HPHA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Heidelberg Pharma AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Heidelberg Pharma AG's Enterprise Value for the quarter that ended in Feb. 2024 was €110.13 Mil.
Heidelberg Pharma AG's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description